51 In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer
Perrone E, Lopez S, Zeibek B, Bellone S, Zammataro L, Manzano A, Bonazzoli E, Manara P, Scambia G, Santin A. 51 In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer. International Journal Of Gynecological Cancer 2019, 29: a29. DOI: 10.1136/ijgc-2019-igcs.51.Peer-Reviewed Original ResearchEpithelial ovarian cancerTrop-2 expressionSacituzumab govitecanPrimary tumor cell linesEOC cell linesTrop-2EOC xenograftsOvarian cancerCell linesTumor cell linesAggressive epithelial ovarian cancerLethal gynecologic malignancyHigh ADCC activityGreater antitumor effectParaffin-embedded tumorsGynecologic malignanciesADCC activityOvarian tumorsPreclinical activityClinical trialsEpithelial tumorsSignificant bystander effectAntitumor effectsStrong stainingActive metabolite